Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GHGet Rating) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $90.39.

Several equities analysts have recently issued reports on GH shares. Craig Hallum started coverage on Guardant Health in a research note on Wednesday, October 19th. They issued a “buy” rating and a $88.00 price objective for the company. The Goldman Sachs Group cut their target price on Guardant Health from $80.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. Cowen cut their target price on Guardant Health from $110.00 to $83.00 in a research report on Friday, November 4th. Bank of America raised their target price on Guardant Health from $65.00 to $70.00 in a research report on Friday, December 16th. Finally, Stephens cut their target price on Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a research report on Monday, November 7th.

Insiders Place Their Bets

In other news, insider Kumud Kalia sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $51.87, for a total value of $162,093.75. Following the transaction, the insider now owns 20,135 shares of the company’s stock, valued at $1,044,402.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GH. Capital International Investors boosted its stake in shares of Guardant Health by 71.0% in the first quarter. Capital International Investors now owns 5,081,624 shares of the company’s stock valued at $336,607,000 after buying an additional 2,110,240 shares in the last quarter. Pictet Asset Management SA boosted its stake in shares of Guardant Health by 206.7% in the second quarter. Pictet Asset Management SA now owns 1,034,652 shares of the company’s stock valued at $41,738,000 after buying an additional 697,281 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Guardant Health in the third quarter valued at approximately $29,182,000. Ensign Peak Advisors Inc boosted its stake in shares of Guardant Health by 1,394.7% in the first quarter. Ensign Peak Advisors Inc now owns 312,084 shares of the company’s stock valued at $20,672,000 after buying an additional 291,204 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its stake in shares of Guardant Health by 285.3% in the second quarter. Integral Health Asset Management LLC now owns 385,291 shares of the company’s stock valued at $15,543,000 after buying an additional 285,291 shares in the last quarter. Institutional investors and hedge funds own 90.43% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $30.43 on Monday. The stock has a 50-day simple moving average of $39.99 and a 200-day simple moving average of $46.95. The company has a debt-to-equity ratio of 6.82, a quick ratio of 6.10 and a current ratio of 6.46. The stock has a market capitalization of $3.12 billion, a PE ratio of -5.13 and a beta of 0.83. Guardant Health has a 1 year low of $24.63 and a 1 year high of $79.24.

Guardant Health (NASDAQ:GHGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). The company had revenue of $117.40 million during the quarter, compared to analysts’ expectations of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative return on equity of 145.58%. On average, analysts predict that Guardant Health will post -6.46 earnings per share for the current fiscal year.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Recommended Stories

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.